No video visit
All states
GLP-1 weight loss in Rhode Island
- Visit type
- One video visit to start
- Licensing
- Rhode Island Board of Medical Licensure and Discipline
- Updated
- Licensed by
- Rhode Island Board of Medical Licensure and Discipline
- Telehealth
- One video visit to start
- Semaglutide injections
- Available
- Tirzepatide injections
- Available
- Medicaid
- Limited coverage
- Shipping
- 2–3 business days
Rhode Island residents can now access GLP-1 medications like semaglutide and tirzepatide through telehealth — from Providence and Warwick to Cranston, Pawtucket, and Newport. Pallas Health connects you with a board-certified provider licensed in Rhode Island who can evaluate your eligibility and, if appropriate, prescribe medication that ships to any Rhode Island address in a few business days.
How telehealth prescribing works in Rhode Island
Rhode Island requires a synchronous (audio-visual) encounter to establish the patient–provider relationship. The Board of Medical Licensure and Discipline mandates that initial telemedicine visits be real-time so the provider and patient can interact and the provider can see the patient. Asynchronous-only encounters are not permitted for initial visits.
Rhode Island requires providers to hold an active Rhode Island medical license (or qualifying equivalent) to treat patients located in the state. Under the Rhode Island Board of Medical Licensure and Discipline telemedicine guidelines, initial telemedicine encounters must be synchronous — the provider and patient must interact in real time via audio-visual technology. Rhode Island does not permit asynchronous-only encounters to establish a new patient relationship. Every Pallas clinician who treats Rhode Island patients is individually licensed and conducts a synchronous video visit before any prescription is issued. Importantly, Rhode Island requires telemedicine providers to post licensure or identifying information about their providers publicly on provider websites (R.I. Board of Medical Licensure and Discipline Telemedicine Guidelines). Pallas publishes its clinical partners (Lion MD and CareValidate), provider leadership, and NPI numbers — with direct links to the federal NPPES NPI Registry — on our clinical disclosures page at pallashealth.co/clinical, where the full prescribing roster's licensure can be verified. GLP-1s are not controlled substances, so Rhode Island's separate Prescription Monitoring Program requirements don't add friction here, but our providers still document a complete history, screen for contraindications like personal or family history of medullary thyroid carcinoma, and schedule follow-up visits to monitor response and titrate the dose.
Medicaid & insurance in Rhode Island
Rhode Island's enacted FY2027 budget, signed June 12, 2026, ends Medicaid coverage of GLP-1s for weight-loss indications effective October 1, 2026. Coverage for type 2 diabetes indications is not affected. Compounded GLP-1s are not covered. Pallas is a cash-pay service, so Medicaid formulary changes do not affect our pricing. Pallas is a cash-pay telehealth service. Medicaid and private insurance do not apply to our prescriptions; pricing is flat and disclosed up front.
Simple cash-pay pricing in Rhode Island
No insurance, and the same price in every Rhode Island ZIP code. You see your full price during intake, before you pay anything. One plan price covers your US-licensed provider, check-ins, dose adjustments and care-team messaging, with no membership fee. Medication ships free, and nothing is charged until a clinician prescribes. Cancel anytime. Your clinician helps determine which option is appropriate for you.
Compounded
- Semaglutide injectionsFrom $139
- Tirzepatide injectionsFrom $179
Brand-name
- Wegovy® injectionsFrom $499
- Zepbound® injectionsFrom $499
- Ozempic® injectionsFrom $499
- Mounjaro® injections$1,099/mo
- Wegovy® pillFrom $299
- Foundayo™ pillFrom $299
Semaglutide vs tirzepatide in Rhode Island
Both are once-weekly injections available to Rhode Island patients through Pallas, as compounded preparations and as the FDA-approved brand-name products. They work differently: semaglutide activates the GLP-1 receptor, while tirzepatide activates both the GLP-1 and GIP receptors — two of the gut hormones that regulate appetite and fullness.
In SURMOUNT-5, the head-to-head clinical trial of the FDA-approved products, Zepbound® (tirzepatide 10 mg or 15 mg weekly) produced greater average weight loss than Wegovy® (semaglutide 1.7 mg or 2.4 mg weekly) — 20.2% versus 13.7% of body weight over 72 weeks — with broadly similar tolerability. That trial predates Wegovy®'s higher 7.2 mg weekly dose, which reached 18.7% average weight loss over 72 weeks in the separate STEP UP trial; separate trials do not provide a direct comparison. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary.
Cost and track record differ too: compounded semaglutide renews at $199 every 4 weeks versus $299 for tirzepatide (full terms in the questions below), and semaglutide has the longer post-market record. Which medication fits your health history, goals, and budget is a decision you make with a clinician licensed in Rhode Island — our full semaglutide vs tirzepatide comparison covers the deeper differences.
Cities served in Rhode Island
Partner pharmacies ship to every ZIP code in Rhode Island, including:
- Providence
- Warwick
- Cranston
- Pawtucket
- East Providence
Rhode Island GLP-1 questions
Yes, one. Rhode Island requires a live video visit to start care. It is included in your plan and scheduled after intake; follow-ups happen by secure message.
Start the online intake (about 5 minutes), then have one video visit with a Rhode Island-licensed clinician. If a GLP-1 is appropriate, a US-licensed pharmacy ships it to you in 2–3 business days.
Same intake as semaglutide. If appropriate, a Rhode Island-licensed clinician can prescribe compounded tirzepatide or FDA-approved Zepbound® or Mounjaro®, and explains which fits you.
Yes. A Rhode Island-licensed clinician can prescribe it for you with a documented clinical reason, and a US-licensed compounding pharmacy prepares it per patient. Brand-name Wegovy® is also available.
Several do. Check that its clinicians are licensed in Rhode Island, that it uses US-licensed compounding pharmacies, and that it is LegitScript-certified. Pallas serves Rhode Island.
Intake takes about 5 minutes, and your video visit with a Rhode Island-licensed clinician is usually within 1 to 2 business days. If prescribed, the pharmacy ships in 2–3 business days.
Yes. Partner pharmacies ship to every Rhode Island ZIP code, from Providence and Warwick to the smallest towns, usually in 2–3 business days. Remote addresses may take an extra day.
Several do. Check that its clinicians hold a Rhode Island license, that it uses US-licensed pharmacies, and that it is LegitScript-certified (the database is public). Pallas serves Rhode Island.
Rhode Island Medicaid stops covering GLP-1s for weight loss on October 1, 2026; type 2 diabetes coverage continues. Compounded GLP-1s are not covered. Pallas is cash-pay, so Medicaid rules do not apply.
One flat cash-pay price, the same in every Rhode Island ZIP code, no insurance needed. It covers your clinician, check-ins and messaging, and medication ships free once prescribed.
A Rhode Island-licensed clinician decides after your intake and video visit. GLP-1s are generally considered at a BMI of 30 or more, or 27 or more with a condition like high blood pressure.
Wegovy®, Ozempic®, Zepbound® and Mounjaro® are FDA-approved. Compounded semaglutide and tirzepatide are made per patient by US-licensed pharmacies and are not FDA-approved. Your clinician decides.
Yes. Tell your clinician your current medication, dose and everything else you take during intake. If appropriate, they continue you at a comparable dose. Don't change a prescription on your own.
Most patients use a once-weekly injection with a very fine needle. A daily tablet is available on request. Your clinician confirms which form is appropriate for you.
Mostly stomach-related: nausea, constipation or diarrhea, usually mildest when the dose is raised slowly. They are avoided in pregnancy and with a personal or family history of medullary thyroid cancer or MEN2.
You answer health questions online in about 5 minutes, then meet a Rhode Island-licensed clinician by video. If a GLP-1 is appropriate, a licensed pharmacy ships it in 2–3 business days.
Your first order arrives in 2–3 business days, and most patients start low and step up gradually. Your plan renews on a set schedule so refills arrive before you run out; change or cancel anytime in the portal.
Yes. Rhode Island nurse practitioners prescribe independently, with no physician agreement required. GLP-1s are not controlled substances, so they can be prescribed after one video visit.
Compounded semaglutide injections are $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. Your clinician, check-ins and messaging are included; shipping is free.
Compounded tirzepatide injections are $179 first month, then $299 every 4 weeks, charged once a clinician prescribes. Cancel anytime. Your clinician, check-ins and messaging are included; shipping is free.
Yes. Wegovy®, Zepbound® and Foundayo™ are FDA-approved for weight management, Ozempic® and Mounjaro® for type 2 diabetes. All are cash-pay: pens from $499 first month, daily pills from $299.
Rhode Island Medicaid stops covering GLP-1s for weight loss on October 1, 2026; type 2 diabetes coverage continues. Compounded GLP-1s are not covered. Pallas is cash-pay, so Medicaid rules do not apply.
Two cash-pay paths: stay on Wegovy® or Zepbound® from $499 first month, or a compounded plan from $139 first month if a licensed clinician finds it appropriate. Tell your clinician your current dose.
A decision for you and your clinician. Semaglutide costs less and has the longer track record; tirzepatide acts on two gut-hormone receptors instead of one. The comparison above covers the trials.
Pallas serves all of Rhode Island with one price for compounded semaglutide: $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. One video visit is included.
Rule changes affecting Rhode Island
- 2026-07-27 Rhode Island's FY2027 budget, signed June 12, 2026, ends Medicaid coverage of GLP-1s for weight-loss indications effective October 1, 2026; type 2 diabetes coverage is unaffected. Our note previously described the change as proposed.Rhode Island Current reporting on the enacted FY27 budget (June 12, 2026); surfaced by our automated source check (PR #45).
- 2026-05-29 Baseline video-visit-required list at tracker inception: New Mexico, Mississippi, Kansas, West Virginia, and Rhode Island (5 jurisdictions). All other states and D.C. permitted asynchronous establishment of care for non-controlled prescriptions.Confirmed with our clinical network's licensing and routing team.
From our state-by-state rules tracker. Get an email when a rule changes.
Pallas offers both FDA-approved and compounded medications. Compounded medications are not FDA-approved and are not generic versions of brand-name drugs. Eligibility and treatment are determined by a US-licensed clinician; results vary. Private pay only (no insurance). Operated by Brentmoor, Inc.